IVD Assay Development
Seraseq® ctDNA Lymphoma Mix AF1%
Details
Resources
Specifications
To help clinical labs performing NGS-based lymphoid testing better develop, characterize, validate and routinely assess lymphoid diseases by NGS assays, SeraCare has developed the Seraseq® Lymphoma DNA Mutation Mix, Seraseq FFPE Lymphoma Reference Material and SeraSeq ctDNA Lymphoma DNA Mutation Mix,, the first set of comprehensive lymphoid cancer NGS assay reference materials. These unique products include clinically important SNVs, INDELs and gene fusions important in lymphoma disease diagnosis and prognosis. Variants are present against a single well-characterized genomic background (GM24385) at clinically relevant allele frequencies, precisely quantitated by digital PCR assays.
FEATURES AND BENEFITS
Seraseq ctDNA Mutation Mix Non-Requirement Letter
Seraseq® Lymphoma DNA Products
Seraseq® ctDNA Lymphoma Mix, AF1%, AF0.5%, AF0.1%
Seraseq ctDNA Lymphoma Mix AF1%